BIOMAT Database Logo BIOMAT Database Logo

Outcomes of acute hepatitis B virus (HBV) in HIV infection with and without HBV-active antiretroviral therapy. 2021

Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Johns Hopkins University, Baltimore, Maryland.

Men with acute hepatitis B virus (HBV) infection in the Multicenter AIDS Cohort Study from 1985 to 2013 had serological testing to determine proportions with HBV recovery or chronic hepatitis B (CHB). A similar proportion of men without human immunodeficiency virus (HIV) and men with HIV receiving HBV-active antiretroviral therapy (ART) developed CHB [8.2%, 95% confidence interval (CI) 3.8-15.0% vs. 7.7%, 95% CI 2.00-36.0%]. In contrast, 17.5% (95% CI 8.7-29.9%) of men living with HIV, not on HBV-active ART developed CHB. HBV-active ART protects against developing CHB.

UI MeSH Term Description Entries
D008297 Male Males
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019694 Hepatitis B, Chronic INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Chronic Hepatitis B,Chronic Hepatitis B Virus Infection,Hepatitis B Virus Infection, Chronic
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral

Related Publications

Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection.
February 2015, Antimicrobial agents and chemotherapy,
Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy.
April 2000, Journal of acquired immune deficiency syndromes (1999),
Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
September 2006, AIDS research and human retroviruses,
Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.
March 2010, Journal of virology,
Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy.
September 2014, The Journal of infectious diseases,
Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.
April 2009, The Journal of infectious diseases,
Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection.
April 2014, AIDS (London, England),
Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection.
April 2005, The Journal of infectious diseases,
Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
November 2007, Journal of medical virology,
Oluwaseun Falade-Nwulia, and Eric C Seaberg, and Anna E Snider, and Charles R Rinaldo, and Steven M Wolinsky, and Mallory D Witt, and Chloe L Thio
Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection.
December 2003, Journal of hepatology,
Copied contents to your clipboard!